DUOPLAVIN Trademark

Trademark Overview

On Monday, April 13, 2009, a trademark application was filed for DUOPLAVIN with the United States Patent and Trademark Office. The USPTO has given the DUOPLAVIN trademark a serial number of 77712828. The federal status of this trademark filing is CANCELLED - SECTION 7 as of Wednesday, October 14, 2015. This trademark is owned by sanofi-aventis. The DUOPLAVIN trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical substances and products for the prevention and the treatment of cardiovascular diseases
duoplavin

General Information

Serial Number77712828
Word MarkDUOPLAVIN
Filing DateMonday, April 13, 2009
Status711 - CANCELLED - SECTION 7
Status DateWednesday, October 14, 2015
Registration Number3724909
Registration DateTuesday, December 15, 2009
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 29, 2009

Trademark Statements

Goods and Servicespharmaceutical substances and products for the prevention and the treatment of cardiovascular diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code1 - Sec. 7(d) - Entire Registration
Class Status DateWednesday, October 14, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSANOFI
Party Type31 - New Owner After Registration
Legal Entity Type99 - Other
AddressParis 75008
FR
Party Namesanofi-aventis
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressParis 75013
FR
Party Namesanofi-aventis
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParis 75013
FR
Party Namesanofi-aventis
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParis 75013
FR

Trademark Events

Event DateEvent Description
Wednesday, October 14, 2015CANCELLED SECTION 7-TOTAL
Wednesday, October 7, 2015REQUEST FOR SECT 7 TOTAL SURRENDER FILED
Wednesday, October 7, 2015CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, October 7, 2015TEAS SECTION 7 SURRENDER RECEIVED
Wednesday, March 7, 2012APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, March 7, 2012TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, June 1, 2011AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, December 15, 2009REGISTERED-PRINCIPAL REGISTER
Tuesday, September 29, 2009PUBLISHED FOR OPPOSITION
Wednesday, September 9, 2009NOTICE OF PUBLICATION
Wednesday, August 26, 2009LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, August 26, 2009APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 25, 2009TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 25, 2009CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, August 21, 2009TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, August 3, 2009NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, August 3, 2009LETTER OF SUSPENSION E-MAILED
Monday, August 3, 2009SUSPENSION LETTER WRITTEN
Friday, July 17, 2009TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 14, 2009CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 14, 2009TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 4, 2009NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 4, 2009NON-FINAL ACTION E-MAILED
Thursday, June 4, 2009NON-FINAL ACTION WRITTEN
Wednesday, June 3, 2009ASSIGNED TO EXAMINER
Friday, April 24, 2009PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, April 22, 2009ASSIGNED TO LIE
Wednesday, April 22, 2009TEAS VOLUNTARY AMENDMENT RECEIVED
Thursday, April 16, 2009NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, April 16, 2009NEW APPLICATION ENTERED IN TRAM

Related Keywords

duoplavin cardiovascular diseases treatment prevention substances products pharmaceutical